Tekla Healthcare Investors of Benef Interest
Name
As of 11/20/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
-4.0%
1 yr return
7.0%
3 Yr Avg Return
-8.3%
5 Yr Avg Return
-3.7%
Net Assets
$934 M
Holdings in Top 10
42.6%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 1.11%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 69.19%
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Closed-end mutual fund
Name
As of 11/20/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
XHQHX - Profile
Distributions
- YTD Total Return -4.0%
- 3 Yr Annualized Total Return -8.3%
- 5 Yr Annualized Total Return -3.7%
- Capital Gain Distribution Frequency N/A
- Net Income Ratio -0.54%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Quarterly
Fund Details
-
Legal NameTekla Healthcare Investors of Benef Interest
-
Fund Family NameTekla Capital Management LLC
-
Inception DateNov 22, 2011
-
Shares Outstanding46343900
-
Share ClassOther
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerDaniel Omstead
Fund Description
XHQHX - Performance
Return Ranking - Trailing
Period | XHQHX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -4.0% | -27.4% | 19.9% | 94.34% |
1 Yr | 7.0% | -13.7% | 48.1% | 94.34% |
3 Yr | -8.3%* | -28.0% | 9.5% | 90.79% |
5 Yr | -3.7%* | -7.8% | 12.2% | 96.58% |
10 Yr | N/A* | 0.2% | 13.1% | 100.00% |
* Annualized
Return Ranking - Calendar
Period | XHQHX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | -5.1% | -12.6% | 19.0% | 93.71% |
2022 | -13.8% | -53.9% | 3.2% | 67.76% |
2021 | -5.4% | -39.6% | 24.2% | 69.08% |
2020 | 8.4% | -13.6% | 178.2% | 71.14% |
2019 | 14.7% | 3.8% | 63.8% | 84.21% |
Total Return Ranking - Trailing
Period | XHQHX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -4.0% | -27.4% | 19.9% | 94.34% |
1 Yr | 7.0% | -13.7% | 48.1% | 94.34% |
3 Yr | -8.3%* | -28.0% | 9.5% | 90.79% |
5 Yr | -3.7%* | -7.8% | 12.2% | 96.58% |
10 Yr | N/A* | 0.2% | 13.1% | 100.00% |
* Annualized
Total Return Ranking - Calendar
Period | XHQHX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | -5.1% | -12.6% | 19.0% | 94.97% |
2022 | -13.8% | -53.9% | 3.7% | 77.63% |
2021 | -5.4% | -33.9% | 26.0% | 87.50% |
2020 | 8.4% | -0.7% | 180.6% | 94.63% |
2019 | 19.2% | 4.6% | 63.8% | 89.47% |
NAV & Total Return History
XHQHX - Holdings
Concentration Analysis
XHQHX | Category Low | Category High | XHQHX % Rank | |
---|---|---|---|---|
Net Assets | 934 M | 6.66 M | 45.7 B | 47.80% |
Number of Holdings | 153 | 25 | 430 | 8.18% |
Net Assets in Top 10 | 473 M | 2.12 M | 22.1 B | 39.62% |
Weighting of Top 10 | 42.64% | 18.4% | 79.7% | 66.67% |
Top 10 Holdings
- Moderna Inc 6.88%
- Amgen Inc 6.56%
- Gilead Sciences Inc 5.59%
- Regeneron Pharmaceuticals Inc 4.46%
- Illumina Inc 4.34%
- Horizon Therapeutics PLC 4.20%
- Seagen Inc Ordinary Shares 4.13%
- Vertex Pharmaceuticals Inc 3.51%
- Seagen Inc Ordinary Shares 3.31%
- Alexion Pharmaceuticals Inc 3.26%
Asset Allocation
Weighting | Return Low | Return High | XHQHX % Rank | |
---|---|---|---|---|
Stocks | 91.62% | 87.34% | 106.13% | 91.82% |
Preferred Stocks | 7.27% | 0.00% | 7.86% | 1.26% |
Cash | 2.13% | 0.00% | 33.01% | 49.69% |
Convertible Bonds | 0.00% | 0.00% | 0.37% | 67.53% |
Bonds | 0.00% | 0.00% | 12.39% | 73.58% |
Other | -1.01% | -22.99% | 23.24% | 98.11% |
Stock Sector Breakdown
Weighting | Return Low | Return High | XHQHX % Rank | |
---|---|---|---|---|
Healthcare | 99.83% | 59.26% | 100.00% | 55.19% |
Financial Services | 0.17% | 0.00% | 1.60% | 16.88% |
Utilities | 0.00% | 0.00% | 0.00% | 65.58% |
Technology | 0.00% | 0.00% | 22.69% | 69.48% |
Real Estate | 0.00% | 0.00% | 5.89% | 67.53% |
Industrials | 0.00% | 0.00% | 7.02% | 69.48% |
Energy | 0.00% | 0.00% | 0.00% | 65.58% |
Communication Services | 0.00% | 0.00% | 9.11% | 68.18% |
Consumer Defense | 0.00% | 0.00% | 25.73% | 68.83% |
Consumer Cyclical | 0.00% | 0.00% | 1.92% | 68.18% |
Basic Materials | 0.00% | 0.00% | 7.16% | 75.32% |
Stock Geographic Breakdown
Weighting | Return Low | Return High | XHQHX % Rank | |
---|---|---|---|---|
US | 85.12% | 66.06% | 104.41% | 74.21% |
Non US | 6.50% | 0.00% | 28.87% | 37.11% |
XHQHX - Expenses
Operational Fees
XHQHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 1.11% | 0.08% | 4.48% | 47.17% |
Management Fee | 1.00% | 0.03% | 1.25% | 91.82% |
12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
XHQHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | N/A | 3.50% | 5.75% | N/A |
Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
XHQHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
XHQHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | 69.19% | 0.00% | 238.00% | 82.22% |
XHQHX - Distributions
Dividend Yield Analysis
XHQHX | Category Low | Category High | XHQHX % Rank | |
---|---|---|---|---|
Dividend Yield | 0.00% | 0.00% | 6.24% | 78.62% |
Dividend Distribution Analysis
XHQHX | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | Quarterly | Annual | Monthly | Annual |
Net Income Ratio Analysis
XHQHX | Category Low | Category High | XHQHX % Rank | |
---|---|---|---|---|
Net Income Ratio | -0.54% | -2.54% | 1.85% | 71.05% |
Capital Gain Distribution Analysis
XHQHX | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Annually | Annually |
Distributions History
Date | Amount | Type |
---|---|---|
May 30, 2019 | $0.450 | OrdinaryDividend |
Feb 27, 2019 | $0.410 | OrdinaryDividend |
Nov 27, 2018 | $0.510 | OrdinaryDividend |
Aug 27, 2018 | $0.470 | OrdinaryDividend |
May 31, 2018 | $0.470 | OrdinaryDividend |
Feb 27, 2018 | $0.480 | OrdinaryDividend |
Nov 27, 2017 | $0.520 | OrdinaryDividend |
Aug 24, 2017 | $0.510 | OrdinaryDividend |
May 30, 2017 | $0.500 | OrdinaryDividend |
Feb 24, 2017 | $0.450 | OrdinaryDividend |
Nov 23, 2016 | $0.500 | OrdinaryDividend |
Aug 25, 2016 | $0.470 | OrdinaryDividend |
May 24, 2016 | $0.490 | OrdinaryDividend |
Feb 26, 2016 | $0.610 | OrdinaryDividend |
Dec 28, 2015 | $0.940 | ExtraDividend |
Nov 23, 2015 | $0.590 | OrdinaryDividend |
Aug 26, 2015 | $0.710 | OrdinaryDividend |
May 22, 2015 | $0.680 | OrdinaryDividend |
Feb 26, 2015 | $0.630 | OrdinaryDividend |
Nov 24, 2014 | $0.590 | OrdinaryDividend |
Aug 27, 2014 | $0.560 | OrdinaryDividend |
May 23, 2014 | $0.540 | OrdinaryDividend |
Feb 27, 2014 | $0.530 | OrdinaryDividend |
Nov 25, 2013 | $0.500 | OrdinaryDividend |
Aug 27, 2013 | $0.440 | OrdinaryDividend |
May 23, 2013 | $0.420 | OrdinaryDividend |
Feb 27, 2013 | $0.370 | OrdinaryDividend |
Nov 19, 2012 | $0.380 | OrdinaryDividend |
Aug 20, 2012 | $0.360 | OrdinaryDividend |
May 21, 2012 | $0.360 | OrdinaryDividend |
Feb 17, 2012 | $0.310 | OrdinaryDividend |
Nov 17, 2011 | $0.290 | OrdinaryDividend |
Aug 19, 2011 | $0.340 | OrdinaryDividend |
May 20, 2011 | $0.320 | OrdinaryDividend |
Feb 16, 2011 | $0.310 | OrdinaryDividend |
Nov 18, 2010 | $0.290 | OrdinaryDividend |
Aug 19, 2010 | $0.170 | OrdinaryDividend |
May 20, 2010 | $0.200 | OrdinaryDividend |
May 20, 2009 | $0.250 | OrdinaryDividend |
Feb 18, 2009 | $0.270 | OrdinaryDividend |
Nov 19, 2008 | $0.330 | OrdinaryDividend |
Aug 20, 2008 | $0.330 | OrdinaryDividend |
May 21, 2008 | $0.340 | OrdinaryDividend |
Feb 20, 2008 | $0.380 | OrdinaryDividend |
Nov 19, 2007 | $0.380 | OrdinaryDividend |
Aug 20, 2007 | $0.370 | OrdinaryDividend |
May 23, 2007 | $0.360 | OrdinaryDividend |
Feb 20, 2007 | $0.350 | OrdinaryDividend |
Nov 17, 2006 | $0.360 | OrdinaryDividend |
Sep 06, 2006 | $0.340 | OrdinaryDividend |
Jun 07, 2006 | $0.390 | OrdinaryDividend |
Feb 16, 2006 | $0.370 | OrdinaryDividend |
Nov 17, 2005 | $0.510 | OrdinaryDividend |
Aug 18, 2005 | $0.360 | OrdinaryDividend |
May 24, 2005 | $0.350 | OrdinaryDividend |
Feb 17, 2005 | $0.370 | OrdinaryDividend |
Nov 18, 2004 | $0.360 | OrdinaryDividend |
Aug 18, 2004 | $0.381 | OrdinaryDividend |
May 21, 2004 | $0.420 | OrdinaryDividend |
Feb 18, 2004 | $0.390 | OrdinaryDividend |
Nov 24, 2003 | $0.610 | OrdinaryDividend |
Aug 07, 2003 | $0.390 | OrdinaryDividend |
May 15, 2003 | $0.330 | OrdinaryDividend |
Feb 18, 2003 | $0.350 | OrdinaryDividend |
Nov 20, 2002 | $1.100 | OrdinaryDividend |
Aug 07, 2002 | $0.410 | OrdinaryDividend |
May 21, 2002 | $0.510 | OrdinaryDividend |
Feb 15, 2002 | $0.610 | OrdinaryDividend |
Nov 16, 2001 | $1.650 | OrdinaryDividend |
Aug 07, 2001 | $0.660 | OrdinaryDividend |
May 08, 2001 | $0.530 | OrdinaryDividend |
Feb 14, 2001 | $0.640 | OrdinaryDividend |
Nov 20, 2000 | $2.950 | OrdinaryDividend |
Aug 21, 2000 | $0.850 | OrdinaryDividend |
May 19, 2000 | $0.740 | OrdinaryDividend |
Feb 17, 2000 | $0.550 | OrdinaryDividend |
Nov 16, 1999 | $0.170 | CapitalGainShortTerm |
Nov 16, 1999 | $1.160 | CapitalGainLongTerm |
Nov 20, 1998 | $0.360 | CapitalGainLongTerm |
Nov 19, 1997 | $1.070 | CapitalGainLongTerm |
Nov 14, 1996 | $4.490 | CapitalGainLongTerm |
Dec 19, 1991 | $0.040 | OrdinaryDividend |
Dec 24, 1990 | $0.055 | OrdinaryDividend |
Dec 21, 1987 | $0.020 | OrdinaryDividend |
XHQHX - Fund Manager Analysis
Managers
Daniel Omstead
Start Date
Tenure
Tenure Rank
Sep 30, 2001
20.68
20.7%
Omstead is president and chief executive officer of Tekla Capital Management, formerly known as Hambrecht & Quist Capital Management, Inc. Before joining the adviser, Omstead was president and CEO of Reprogenesis, Inc., a private development stage biotech company developing therapies in the field of regenerative medicine. Before joining Reprogenesis, he was senior vice president, research and development at Cytotherapeutics, Inc., a public biotech company that developed CNS therapies.
Tenure Analysis
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.02 | 24.72 | 7.88 | 0.25 |